Literature DB >> 19028201

Immunity from smallpox vaccine persists for decades: a longitudinal study.

Dennis D Taub1, William B Ershler, Mark Janowski, Andrew Artz, Michael L Key, Julie McKelvey, Denis Muller, Bernard Moss, Luigi Ferrucci, Patricia L Duffey, Dan L Longo.   

Abstract

PURPOSE: The threat of smallpox resulting from bioterrorist action has prompted a reassessment of the level of immunity in current populations.
METHODS: We have examined the magnitude and duration of antiviral antibody immunity conferred by smallpox vaccination in 246 participants of the Baltimore Longitudinal Study of Aging. Of this population, 209 subjects were vaccinated one or more times 13 to 88 years before this evaluation, and stored serum samples were available at various intervals after vaccination. An additional 8 subjects who had documented childhood smallpox infection and 29 subjects with no history of infection or vaccination were included. We quantified the total vaccinia IgG and neutralizing antibody titers in each of these subgroups of participants over time.
RESULTS: Vaccinated participants maintained antivaccinia IgG and neutralizing antibody titers above 3 natural logs essentially indefinitely. The absolute titer of antivaccinia antibody was only slightly higher after multiple vaccinations. In 97% of the participants, no decrease in vaccinia-specific antibody titers was noted with age over a follow-up period of up to 88 years. Moreover, Baltimore Longitudinal Study of Aging participants who survived active smallpox infections in their youth retained antivaccinia antibody titers that were similar to the levels detected in vaccinated subjects.
CONCLUSION: These data suggest that multiple or recent vaccinations are not essential to maintain vaccinia-specific antibody responses in human subjects. Scarce vaccine supplies should be applied first to individuals who have not previously been vaccinated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028201      PMCID: PMC2610468          DOI: 10.1016/j.amjmed.2008.08.019

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  30 in total

1.  Analysis of historical data suggests long-lasting protective effects of smallpox vaccination.

Authors:  Martin Eichner
Journal:  Am J Epidemiol       Date:  2003-10-15       Impact factor: 4.897

2.  New data in a 200-year investigation.

Authors:  Mike Bray
Journal:  Clin Infect Dis       Date:  2003-12-08       Impact factor: 9.079

3.  Duration of antiviral immunity after smallpox vaccination.

Authors:  Erika Hammarlund; Matthew W Lewis; Scott G Hansen; Lisa I Strelow; Jay A Nelson; Gary J Sexton; Jon M Hanifin; Mark K Slifka
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

4.  Responses to smallpox vaccine.

Authors:  Jeffrey A Frelinger; Mohammed L Garba
Journal:  N Engl J Med       Date:  2002-08-29       Impact factor: 91.245

5.  [Detection for severe acute respiratory syndrome (SARS) coronavirus RNA in stool of SARS patients].

Authors:  Zhong-ping He; Qing-ming Dong; Shu-jing Song; Lin He; Hui Zhuang
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2004-03

6.  Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein.

Authors:  Patricia L Earl; Jeffrey L Americo; Bernard Moss
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 7.  Immunity and immunological memory following smallpox vaccination.

Authors:  Ian J Amanna; Mark K Slifka; Shane Crotty
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

8.  Renal lymphoma associated with Castleman's disease.

Authors:  Takehisa Onishi; Shigenori Yonemura; Yuko Sakata; Yoshiki Sugimura
Journal:  Scand J Urol Nephrol       Date:  2004

9.  Smallpox: anything to declare?

Authors:  Geoffrey L Smith; Grant McFadden
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

10.  [Comparison of the profiles of hypertensive patients seen at the emergency department and in ambulatory care].

Authors:  Cristiane Garcia Sanchez; Angela Maria Geraldo Pierin; Décio Mion Júnior
Journal:  Rev Esc Enferm USP       Date:  2004-03       Impact factor: 1.086

View more
  48 in total

1.  Antiviral immunity following smallpox virus infection: a case-control study.

Authors:  Erika Hammarlund; Matthew W Lewis; Jon M Hanifin; Motomi Mori; Caroline W Koudelka; Mark K Slifka
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys.

Authors:  Rafal J Zielinski; Jeremy V Smedley; Pin-Yu Perera; Peter M Silvera; Thomas A Waldmann; Jacek Capala; Liyanage P Perera
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

3.  Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.

Authors:  Jesse D Troy; Heather R Hill; Marian G Ewell; Sharon E Frey
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

4.  Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Authors:  Angela Huttner; Selidji Todagbe Agnandji; Christophe Combescure; José F Fernandes; Emmanuel Bache Bache; Lumeka Kabwende; Francis Maina Ndungu; Jessica Brosnahan; Thomas P Monath; Barbara Lemaître; Stéphane Grillet; Miriam Botto; Olivier Engler; Jasmine Portmann; Denise Siegrist; Philip Bejon; Peter Silvera; Peter Kremsner; Claire-Anne Siegrist
Journal:  Lancet Infect Dis       Date:  2018-04-05       Impact factor: 25.071

5.  Proof of long-term immunological memory in cartilaginous fishes.

Authors:  Oliver Eve; Hanover Matz; Helen Dooley
Journal:  Dev Comp Immunol       Date:  2020-03-09       Impact factor: 3.636

6.  Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells.

Authors:  Alicia Báez; José I Piruat; Teresa Caballero-Velázquez; Luís I Sánchez-Abarca; Isabel Álvarez-Laderas; M Victoria Barbado; Estefanía García-Guerrero; África Millán-Uclés; Jesús Martín-Sánchez; Mayte Medrano; José Antonio Pérez-Simón
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

7.  The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein.

Authors:  Kaori Shinoda; Linda S Wyatt; Bernard Moss
Journal:  Virology       Date:  2010-06-17       Impact factor: 3.616

Review 8.  Harnessing CD4⁺ T cell responses in HIV vaccine development.

Authors:  Hendrik Streeck; M Patricia D'Souza; Dan R Littman; Shane Crotty
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

Review 9.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 10.  The immunology of smallpox vaccines.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Robert M Jacobson; Gregory A Poland
Journal:  Curr Opin Immunol       Date:  2009-06-11       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.